$ASMB
Assembly Biosciences Inc

2023 Q3 Form 10-Q Financial Statement

#000095017023040626 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.220M $4.970M $6.781M
YoY Change -19.94% -26.71% -1.97%
% of Gross Profit
Research & Development $10.82M $12.52M $17.79M
YoY Change -40.3% -29.61% 6.23%
% of Gross Profit
Depreciation & Amortization $120.0K $126.0K $120.0K
YoY Change -10.45% 5.0% 2.56%
% of Gross Profit
Operating Expenses $15.05M $17.49M $24.57M
YoY Change -35.7% -28.83% 3.83%
Operating Profit -$15.05M -$17.49M -$24.57M
YoY Change -35.7% -28.83% 3.83%
Interest Expense $630.0K $590.0K $112.0K
YoY Change 146.09% 426.79% 57.75%
% of Operating Profit
Other Income/Expense, Net $628.0K $592.0K $112.0K
YoY Change 145.31% 428.57% 57.75%
Pretax Income -$14.42M -$16.90M -$24.46M
YoY Change -37.7% -30.91% 3.67%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$14.42M -$16.90M -$24.46M
YoY Change -37.7% -30.93% 3.67%
Net Earnings / Revenue
Basic Earnings Per Share -$0.27 -$0.32 -$0.51
Diluted Earnings Per Share -$0.27 -$0.32 -$506.5K
COMMON SHARES
Basic Shares Outstanding 52.61M 52.12M 48.29M
Diluted Shares Outstanding 52.57M 52.26M 48.29M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.21M $59.83M $116.7M
YoY Change -57.47% -48.73% -41.38%
Cash & Equivalents $26.66M $21.62M $43.06M
Short-Term Investments $19.55M $38.21M $73.63M
Other Short-Term Assets $3.500M $3.908M $7.082M
YoY Change -32.45% -44.82% 14.52%
Inventory
Prepaid Expenses
Receivables $0.00 $342.0K $523.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $49.67M $64.08M $124.3M
YoY Change -56.84% -48.44% -39.53%
LONG-TERM ASSETS
Property, Plant & Equipment $561.0K $541.0K $5.610M
YoY Change -35.29% -90.36% -36.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $11.91M
YoY Change
Other Assets $552.0K $332.0K $1.635M
YoY Change -65.78% -79.69% -73.17%
Total Long-Term Assets $1.957M $2.496M $19.15M
YoY Change -69.6% -86.97% -66.15%
TOTAL ASSETS
Total Short-Term Assets $49.67M $64.08M $124.3M
Total Long-Term Assets $1.957M $2.496M $19.15M
Total Assets $51.63M $66.58M $143.4M
YoY Change -57.51% -53.59% -45.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $758.0K $904.0K $2.454M
YoY Change -60.97% -63.16% -14.38%
Accrued Expenses $3.886M $4.188M $12.51M
YoY Change -31.66% -66.51% 189.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.132M $8.831M $14.96M
YoY Change -53.87% -40.97% 7.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.800M $2.797M $4.506M
YoY Change -23.31% -37.93% -67.59%
Total Long-Term Liabilities $2.800M $2.797M $4.506M
YoY Change -23.31% -37.93% -67.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.132M $8.831M $14.96M
Total Long-Term Liabilities $2.800M $2.797M $4.506M
Total Liabilities $9.915M $11.63M $19.47M
YoY Change -48.12% -40.27% -35.84%
SHAREHOLDERS EQUITY
Retained Earnings -$774.8M -$760.4M
YoY Change 10.35%
Common Stock $816.8M $815.6M
YoY Change 1.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.71M $54.95M $124.0M
YoY Change
Total Liabilities & Shareholders Equity $51.63M $66.58M $143.4M
YoY Change -57.51% -53.59% -45.28%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$14.42M -$16.90M -$24.46M
YoY Change -37.7% -30.93% 3.67%
Depreciation, Depletion And Amortization $120.0K $126.0K $120.0K
YoY Change -10.45% 5.0% 2.56%
Cash From Operating Activities -$13.84M -$13.63M -$17.89M
YoY Change -30.18% -23.8% -18.0%
INVESTING ACTIVITIES
Capital Expenditures $130.0K $48.00K $0.00
YoY Change -227.45% -100.0%
Acquisitions
YoY Change
Other Investing Activities $19.02M -$8.317M $9.597M
YoY Change -39.68% -186.66% -411.29%
Cash From Investing Activities $18.88M -$8.365M $9.597M
YoY Change -39.93% -187.16% -410.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $177.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 134.0K 177.0K
YoY Change -24.29% -97.12%
NET CHANGE
Cash From Operating Activities -13.84M -13.63M -17.89M
Cash From Investing Activities 18.88M -8.365M 9.597M
Cash From Financing Activities 0.000 134.0K 177.0K
Net Change In Cash 5.040M -21.86M -8.111M
YoY Change -56.59% 169.5% -56.73%
FREE CASH FLOW
Cash From Operating Activities -$13.84M -$13.63M -$17.89M
Capital Expenditures $130.0K $48.00K $0.00
Free Cash Flow -$13.97M -$13.68M -$17.89M
YoY Change -29.16% -23.53% -18.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001426800
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35005
dei Entity Registrant Name
EntityRegistrantName
ASSEMBLY BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8729264
dei Entity Address Address Line1
EntityAddressAddressLine1
331 Oyster Point Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Fourth Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
509-4583
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
ASMB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52614194
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21623000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52418000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38208000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39192000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
342000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
944000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3908000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4413000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
64081000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96967000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
541000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
743000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1623000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3195000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
332000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
889000
CY2023Q2 us-gaap Assets
Assets
66577000
CY2022Q4 us-gaap Assets
Assets
101794000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
904000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2493000
CY2023Q2 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2037000
CY2022Q4 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3122000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4188000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7317000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1702000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3364000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8831000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16296000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2733000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2733000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
101000
CY2023Q2 us-gaap Liabilities
Liabilities
11628000
CY2022Q4 us-gaap Liabilities
Liabilities
19130000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52450731
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52450731
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48894973
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48894973
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
52000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
49000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
815588000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
807938000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-325000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-803000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-760366000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-724520000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54949000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
82664000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66577000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101794000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12523000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17792000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27070000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34997000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4965000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6781000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9977000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12738000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
17488000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
24573000
us-gaap Operating Expenses
OperatingExpenses
37047000
us-gaap Operating Expenses
OperatingExpenses
47735000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17488000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24573000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37047000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47735000
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
592000
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
112000
us-gaap Interest Income Other
InterestIncomeOther
1201000
us-gaap Interest Income Other
InterestIncomeOther
183000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
592000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
112000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1201000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
183000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16896000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24461000
us-gaap Net Income Loss
NetIncomeLoss
-35846000
us-gaap Net Income Loss
NetIncomeLoss
-47552000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3005000
us-gaap Net Income Loss
NetIncomeLoss
-47552000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
123980000
us-gaap Profit Loss
ProfitLoss
-35846000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
188000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-90000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
478000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-579000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16708000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24551000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35368000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48131000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52260088
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52260088
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48293495
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48293495
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51638928
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51638928
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48208735
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48208735
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
70333000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
54000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
188000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1190000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16896000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54949000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
146791000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
177000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-90000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1563000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24461000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
123980000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
82664000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4546000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
478000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3027000
us-gaap Net Income Loss
NetIncomeLoss
-35846000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54949000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
168929000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
177000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-579000
us-gaap Profit Loss
ProfitLoss
-47552000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
250000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
240000
us-gaap Share Based Compensation
ShareBasedCompensation
3025000
us-gaap Share Based Compensation
ShareBasedCompensation
3024000
asmb Accretion Amortization Of Investments In Marketable Debt Securities
AccretionAmortizationOfInvestmentsInMarketableDebtSecurities
221000
asmb Accretion Amortization Of Investments In Marketable Debt Securities
AccretionAmortizationOfInvestmentsInMarketableDebtSecurities
-214000
asmb Noncash Rent Expense
NoncashRentExpense
1709000
asmb Noncash Rent Expense
NoncashRentExpense
1784000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-602000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
187000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-505000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-159000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-557000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-68000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1589000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-205000
asmb Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-1085000
asmb Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
1046000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3127000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2132000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1836000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1846000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37056000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45387000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
24645000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
46500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
22962000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
15854000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
12000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1635000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42646000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4546000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
80000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
177000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4626000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
177000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30795000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2564000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52418000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45627000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21623000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43063000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
171000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
asmb Number Of Approved Products
NumberOfApprovedProducts
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates of costs incurred but not yet invoiced for research and development accruals.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Company’s estimates and could cause actual results to differ materially from those estimates and assumptions.</span></p>
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16896000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24461000
us-gaap Net Income Loss
NetIncomeLoss
-35846000
us-gaap Net Income Loss
NetIncomeLoss
-47552000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52260088
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52260088
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48293495
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48293495
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51638928
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51638928
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48208735
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48208735
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11600457
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8979368
CY2023Q2 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
38260000
CY2023Q2 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
4000
CY2023Q2 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
56000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38208000
CY2023Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
58481000
CY2023Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
4000
CY2023Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
56000
CY2023Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
58429000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
39722000
CY2022Q4 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
0
CY2022Q4 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
530000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39192000
CY2022Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
89398000
CY2022Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2022Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
530000
CY2022Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
88868000
CY2023Q2 asmb Accured Interest Receivable
AccuredInterestReceivable
100000
CY2022Q4 asmb Accured Interest Receivable
AccuredInterestReceivable
300000
CY2023Q2 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3915000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6228000
CY2023Q2 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
99000
CY2022Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
599000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
174000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
490000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4188000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7317000
CY2022Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.30
CY2022Q3 us-gaap Severance Costs1
SeveranceCosts1
1000000
CY2022Q3 asmb Restructuring One Time Termination Cost
RestructuringOneTimeTerminationCost
800000
CY2022Q3 asmb Restructuring Costs Reversal Of Stock Based Compensation Expense
RestructuringCostsReversalOfStockBasedCompensationExpense
700000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
1000000
us-gaap Restructuring Charges
RestructuringCharges
1000000
CY2023Q2 asmb Cumulative Restructuring Charges
CumulativeRestructuringCharges
1100000
asmb Schedule Of Accrued Restructuring Charges Table Textblock
ScheduleOfAccruedRestructuringChargesTableTextblock
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of accrued restructuring charges, included as a component of other accrued expenses on the Company's condensed consolidated balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023, is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.783%;"></td> <td style="width:2.771%;"></td> <td style="width:1.0%;"></td> <td style="width:27.446%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(206,241,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued balance as of December 31, 2022</span></p></td> <td style="background-color:rgba(206,241,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(206,241,254,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(206,241,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">599</span></p></td> <td style="background-color:rgba(206,241,254,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions for cash payments</span></p></td> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(206,241,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued balance as of June 30, 2023</span></p></td> <td style="background-color:rgba(206,241,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(206,241,254,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(206,241,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(206,241,254,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2022Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
599000
us-gaap Payments For Restructuring
PaymentsForRestructuring
500000
CY2023Q2 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
99000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1190000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1581000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3025000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3024000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
5000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2023Q2 asmb Share Based Compensation Arrangement Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice
0.97
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.776
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0382
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y6M
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
800000
asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
100000
asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
100000

Files In Submission

Name View Source Status
0000950170-23-040626-index-headers.html Edgar Link pending
0000950170-23-040626-index.html Edgar Link pending
0000950170-23-040626.txt Edgar Link pending
0000950170-23-040626-xbrl.zip Edgar Link pending
asmb-20230630.htm Edgar Link pending
asmb-20230630.xsd Edgar Link pending
asmb-ex31_1.htm Edgar Link pending
asmb-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
asmb-20230630_def.xml Edgar Link unprocessable
asmb-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
asmb-20230630_htm.xml Edgar Link completed
asmb-20230630_cal.xml Edgar Link unprocessable
asmb-20230630_pre.xml Edgar Link unprocessable